Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Conditions
Brief summary
Objective response rate (ORR) assessed by an independent central review (ICR).
Detailed description
Duration of Response (DoR), Disease control rate (DCR), Progression Free Survival (PFS) per ICR, Overall Survival (OS), Time to deterioration in cough or pain or dyspnea as measured respectively by the cough, pain, and dyspnea items of the European Organization Lung Cancer Module 13 (EORTC QLQ-LC13)., Time to deterioration of physical functioning as measured by the physical functioning domain of the EORTC-QLQ-Core 30 (EORTC QLQ-C30)., Change from baseline in quality of life as measured by the global health status/quality of life domain of the EORTC QLQ-C30.
Interventions
Sponsors
Abbvie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) assessed by an independent central review (ICR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response (DoR), Disease control rate (DCR), Progression Free Survival (PFS) per ICR, Overall Survival (OS), Time to deterioration in cough or pain or dyspnea as measured respectively by the cough, pain, and dyspnea items of the European Organization Lung Cancer Module 13 (EORTC QLQ-LC13)., Time to deterioration of physical functioning as measured by the physical functioning domain of the EORTC-QLQ-Core 30 (EORTC QLQ-C30)., Change from baseline in quality of life as measured by the global health status/quality of life domain of the EORTC QLQ-C30. | — |
Countries
France, Germany, Italy, Romania, Spain
Outcome results
None listed